Andrew Carney joined ARPA-H in July 2023 from HSBC’s Cybersecurity Science and Analytics group, where he worked as a principal researcher. He has over 15 years of experience in software and hardware vulnerability research, technical education and training, and management of research and development teams. In addition to his role as program manager with ARPA-H, Carney holds a joint program manager appointment with the Defense Advanced Research Projects Agency (DARPA) for the AI Cyber Challenge (AIxCC), a competition focused on securing software in critical infrastructure. 

Tracy Warren is an influential leader who devotes deep experience in entrepreneurship and early-stage venture capital investing to American Heart Association Ventures as Senior Managing Director. Passionate about women’s and children’s health, she leads the investment strategy for the Go Red for Women Venture Fund. Tracy is a co-inventor on three patents and has authored numerous articles on early nutrition and pediatric care. Among many board positions, Tracy served on the Board of the Children’s Research Institute at Children’s National Medical Center, where she chaired the Technology & Innovation Advisory Committee, and the Clemson University Research Foundation Board.

Jonathan Behr, Ph.D., has two decades of venture and venture creation experience. He most recently co-led the Dementia Discovery Fund (DDF) as a Partner at SV Health Investors for seven years, having served as a Director or Observer on the Boards of DDF portfolio companies including Caraway Therapeutics (acquired by MRK)  Montara Therapeutics, Nitrase Therapeutics, QurAlis, Sudo Therapeutics, Transposon Therapeutics and Violet Therapeutics. Jon was also the first Managing Director of the T1D Fund, where he built the fund’s investment strategy, team, and portfolio, leading to notable successes such as Inversago Therapeutics (acquired by NVO), Pandion Therapeutics (PAND, acquired by MRK), Provention Bio (PRVB, acquired by SNY), and Semma Tx (acquired by VRTX).  

As a Director for Alloy Therapeutics’ Alloy Foundation, Natalie Lundsteen manages entrepreneurship education initiatives and programs, including Alloy Futures, a Dallas-based biotech startup academy supporting the growth and development of the North Texas life science ecosystem. With a background in career and professional development for scientists, Natalie has taught, mentored, and advised students, postdocs, faculty and alumni at Boston University, Stanford University, Oxford University, Massachusetts Institute of Technology, UT Southwestern Medical Center, Burnett School of Medicine at TCU, and the University of Rhode Island. 

Richard Nevins is the Assistant Executive Director of the Arlington TX Economic Development Corporation. With more than 20 years of experience in economic development, Richard has led major economic development projects, negotiated hundreds of millions in incentives, and helped bring billions of dollars in investment and thousands of jobs to various communities.  His work spans both the public and private sectors, including leadership roles in Arlington, Grand Prairie, Mansfield, and BNSF Railway.

Stephanie Kallay is Senior Director of Patient Advocacy at Crinetics Pharmaceuticals, where she built the company’s patient advocacy function and made patient insight an expected input into business decision-making across the product lifecycle. By embedding the patient perspective from development through commercialization, she has helped position patient advocacy as a driver of smarter strategy, stronger launch readiness, and competitive advantage. Stephanie brings more than 25 years of experience across commercialization, patient advocacy, sales, marketing, and training, with prior roles at Eli Lilly, Solstice Pharmaceuticals, Nestlé, and Merz Pharmaceuticals.

Dean Hart is a healthcare and biotechnology executive with more than 40 years of experience leading growth, commercialization, and innovation across the life sciences industry. He is the Founder and CEO of CommEx Consulting, where he advises pharmaceutical, biotechnology, and medical technology organizations on launch excellence, leadership development, and commercial effectiveness. Throughout his career, Dean has supported more than 20 life sciences companies, including numerous rare disease organizations, in preparing for and executing successful product launches.

With 25+ years of experience in local, state and national public affairs, Allison Griffin is the founder and president of Griffin Strategies, Inc., a Dallas-based communications consulting firm offering reputation management, message development and storytelling, issue advocacy, grassroots and coalition development, media relations, and event production for corporate, non-profit, governmental and political clients since 2003. For the past dozen years, Ms. Griffin has collaborated with patient advocates, healthcare provider organizations, bioscience companies, and other stakeholders to raise awareness and build support for healthcare-related public policy issues at the state and federal levels.